Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anti-typhoid vaccines].

P Morand1, J P Stahl

  • 1Laboratoire de bactériologie-virologie, CHU Grenoble.

La Revue Du Praticien
|November 15, 1992
PubMed
Summary
This summary is machine-generated.

Three typhoid fever vaccines are available, offering 50-96% efficacy. Newer vaccines are recommended over older inactivated ones due to fewer adverse reactions, improving typhoid prevention strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.

Infectious diseases now·2025
Same author

Vaccination of teenagers in France over a 10-year period (2012-2021).

Infectious diseases now·2024
Same author

SPILF update on bacterial arthritis in adults and children.

Infectious diseases now·2023
Same author

'Treatment of Coxiella burnetii endocarditis with hydroxychloroquine' - Author's reply.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2022
Same author

Utilization of macrolides. State of the art 2022 Spilf and GPIP.

Infectious diseases now·2022
Same author

Treatment of Coxiella burnetii endocarditis with hydroxychloroquine. Is it evidence-based?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2022
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Typhoid fever remains a significant global health concern.
  • Several vaccines exist for typhoid fever prevention.
  • Evaluating vaccine efficacy and safety is crucial for public health.

Purpose of the Study:

  • To review and compare the efficacy and safety of available typhoid fever vaccines.
  • To inform vaccine selection for typhoid fever prevention.

Main Methods:

  • Comparative review of existing typhoid fever vaccines.
  • Analysis of reported protective efficacy data.
  • Assessment of adverse reaction profiles for each vaccine type.

Main Results:

Related Experiment Videos

  • Parenteral inactivated whole cell vaccine: 50-88% efficacy.
  • Oral live attenuated vaccine (strain Ty21a): 50-96% efficacy.
  • Parenteral polysaccharide vaccine (Vi): 75-80% efficacy.
  • Inactivated vaccine has a higher frequency of notable adverse reactions.

    • Conclusions:

    • Newer typhoid fever vaccines demonstrate comparable or superior efficacy to older inactivated vaccines.
    • Reduced adverse reactions associated with newer vaccines support their preferential use.
    • Vaccine choice impacts the effectiveness and safety of typhoid fever control programs.